Scrotal Ulcer Due to Lenvatinib During Treatment of Unresectable Hepatocellular Carcinoma
DOI:
https://doi.org/10.60591/crspmi.328Palavras-chave:
Carcinoma, Hepatocellular/drug therapy, Lenvatinib/adverse effects, Skin Ulcer/chemically inducedResumo
Lenvatinib is used as an anti-cancer drug in patients with unresectable hepatocellular carcinoma (HCC) due to its antiangiogenic activity. This class of targeted therapy has changed the paradigm of HCC treatment, but it also poses an additional challenge due to its distinct side effects compared to conventional chemotherapy.
We present the case of a 58-year-old man with Child-Pugh A alcoholic and dysmetabolic cirrhosis, diagnosed with unresectable BCLC (Barcelona Clinic Liver Cancer) stage C HCC. He was started on lenvatinib, and after 4 months of treatment, a skin ulcer appeared on the scrotum. This led to further investigation into its cause and, eventually, to the discontinuation of lenvatinib. The ulcer resolved with drug withdrawal alone (without the need for specific treatment).
This case highlights the importance of clinicians being aware of adverse skin effects associated with lenvatinib, which most likely result from its antiangiogenic activity.
Downloads
Referências
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-73. doi: 10.1016/S0140-6736(18)30207-1.
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681–93. doi: 10.1016/j.jhep.2021.11.018
Goel A, Singla A. Lenvatinib: A narrative drug review. Cancer Res Stat Treat. 2021;4:709.
Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7:2641-53. doi: 10.1002/cam4.1517.
Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019;77:20-8. doi: 10.1016/j.ctrv.2019.05.004.
Barone M, Grani G, Ramundo V, Garritano T, Durante C, Falcone R. Fournier's gangrene during lenvatinib treatment: A case report. Mol Clin Oncol. 2020;12:588-91. doi: 10.3892/mco.2020.2031.
Kim BH, Yu SJ, Kang W, Cho SB, Park SY, Kim SU, et al. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma. J Gastroenterol Hepatol. 2022;37:428-39. doi: 10.1111/jgh.15727.
Ikeda M, Kobayashi M, Tahara M, Kaneko S. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. Expert Opin Drug Saf. 2018;17:1095–105. doi: 10.1080/14740338.2018.1530212
Cha S, Kim DW, Choe JW, Kim TH, Kim SY, Hyun JJ, et al. A case report of a patient presented with skin ulcer after treatment of lenvatinib. J Liver Cancer. 2021;21:194–8. doi: 10.17998/jlc.2021.09.20.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45. doi: 10.1038/clpt.1981.154.
Dohmen K. Severe ulcerative skin lesions due to lenvatinib. Clin Gastroenterol Hepatol. 2020;18:e113. doi: 10.1016/j.cgh.2019.05.005
Kitamura M, Hayashi T, Suzuki C, Hirano S, Tateya I, Kishimoto Y, et al. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report. World J Surg Oncol. 2017;15:24. doi: 10.1186/s12957-017-1096-5.
Sally R, Ugonabo N, Nguyen A, Kim RH, Lo Sicco K. Lenvatinib-induced psoriasiform eruption and palmoplantar erythema in a patient with hepatocellular carcinoma. JAAD Case Rep. 2021;15:1-3. doi: 10.1016/j.jdcr.2021.07.001.
Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, Dahut WL CE. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol. 2015;151:170–7. doi: 10.1001/jamadermatol.2014.2734
Downloads
Publicado
Como Citar
Edição
Secção
Categorias
Licença
Direitos de Autor (c) 2025 Cecília Moreira
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
